"Dioxoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D004149
|
| MeSH Number(s) |
D03.383.246
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dioxoles".
Below are MeSH descriptors whose meaning is more specific than "Dioxoles".
This graph shows the total number of publications written about "Dioxoles" by people in this website by year, and whether "Dioxoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 2 | 4 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dioxoles" by people in Profiles.
-
von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct; 19(10):1802-9.
-
Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol. 2005 Dec; 27(6):1605-16.
-
Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Aug 15; 98(4):832-40.
-
Louneva N, Saitta B, Herrick DJ, Jimenez SA. Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. J Biol Chem. 2003 Oct 10; 278(41):40400-7.
-
Banwait KS, Rattan S. Role of nitric oxide in beta3-adrenoceptor activation on basal tone of internal anal sphincter. Am J Physiol Gastrointest Liver Physiol. 2003 Sep; 285(3):G547-55.
-
Sarma DN, Banwait K, Basak A, DiMarino AJ, Rattan S. Inhibitory effect of beta3-adrenoceptor agonist in lower esophageal sphincter smooth muscle: in vitro studies. J Pharmacol Exp Ther. 2003 Jan; 304(1):48-55.
-
Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, Cerisano V, Strammiello R, Mercuri M, Reverter-Branchat G, Faircloth G, D'Incalci M, Picci P. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res. 2002 Dec; 8(12):3893-903.
-
Dimarino M, Banwait K, Rattan S, Cohen S, DiMarino AJ. Beta3 adrenergic stimulation inhibits the opossum lower esophageal sphincter. Gastroenterology. 2002 Nov; 123(5):1508-15.
-
Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002 Jun 15; 62(12):3377-81.
-
Panwalker AP, Giamarellou H, Jackson GG. Efficacy of cinoxacin in urinary tract infections. Antimicrob Agents Chemother. 1976 Mar; 9(3):502-5.